#prognostic biomarkers

[creativeera]

Cancer Biomarkers Market is Trending by Increasing Personalized Care

Cancer biomarkers are biological molecules found in blood, tissues, or other body fluids whose presence indicates normal or abnormal processes, or conditions of concern regarding health. They are used in patient diagnosis, staging, treatment selection, monitoring of cancer progression or recurrence. Cancer biomarkers help in early cancer detection and assessing the likelihood of cancer recurrence after treatment. They play an important role in cancer risk assessment, screening, diagnosis, prognosis, and predicting treatment response for a variety of cancers. With increasing technological advancements, more personalized and targeted treatment options are emerging. This is fueling the demand for cancer biomarkers to help physicians detect cancer in early stages, determine the best treatment for each patient, monitor the effectiveness of treatment, and check for signs of recurrence.

The Global Cancer Biomarkers Market is estimated to be valued at US$ 25.60 billion in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the Cancer Biomarkers are Schlumberger Limited, Rockwell Automation Inc., SIS-TECH Solutions LP, Emerson Electric Company, HIMA Paul Hildebrandt GmbH, Honeywell International Inc., Siemens AG, Yokogawa Electric Corporation, Schneider Electric SE, and ABB Ltd. The increasing prevalence of cancer globally has boosted the usage of cancer biomarkers. Rising demand for non-invasive diagnostic techniques along with increasing funding for cancer research are fueling the market growth. Growing awareness regarding the benefits of early detection of cancer is further driving the demand for cancer biomarkers. The growing Cancer Biomarkers Market demand for personalized medicine is also propelling the demand for cancer biomarkers. Personalized medicine focuses on classifying individuals based on their susceptibility and likely response to particular treatment. This allows clinicians to choose the most safe and effective treatment for each patient. Many companies are increasingly investing in biomarker research and development to introduce innovative cancer diagnostics and targeted therapies. The increasing global incidence of cancer has encouraged market players to expand their geographical presence. Emerging countries in Asia Pacific and Latin America offer lucrative opportunities for players due to growing healthcare investments, favorable government policies, and rising patient disposable incomes in these regions. Players are also focusing on partnerships, mergers, acquisitions, and collaborations with research institutes and biotechs to strengthen their product portfolios and geographical footprints. Market Key Trends Next-generation sequencing (NGS) has emerged as a key trend in the global cancer biomarkers market. NGS helps to discover and validate novel biomarkers by generating huge amounts of DNA sequence data from tumor and normal samples. It allows comprehensive genomic profiling of tumors to guide treatment decisions. NGS enables the analysis of multiple biomarkers simultaneously compared to traditional techniques. This allows physicians to obtain a complete molecular profile of the tumor specific to each patient for precision diagnosis and treatment selection.

Porter’s Analysis Threat of new entrants: High capital requirements and strong intellectual property rights protections limit new entrants in this competitive market.

Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power over biotech companies developing novel biomarkers, putting pricing pressure.

Bargaining power of suppliers: Suppliers of analytical instruments and clinical testing kits have some bargaining power as they provide core tools and technologies needed by most companies in this space.

Threat of new substitutes: Biomarkers able to better diagnose, monitor, or predict therapeutic responses could emerge as substitutes over time.

Competitive rivalry: Intense competition exists among large pharmaceutical companies and smaller biotech firms to develop and commercialize novel cancer biomarker diagnostic tests and services. Geographical Regions North America currently accounts for the largest share of the global cancer biomarkers market, in terms of value, owing to the high adoption of advanced cancer diagnostic techniques and presence of leading biomarker testing companies in the region. The Asia Pacific market is expected to grow at the fastest rate during the forecast period, due to growing awareness regarding early cancer detection, increasing healthcare expenditure, and expanding base of pharma & biotech companies in China, India, and other Asia Pacific countries.

Get more insights on Cancer Biomarkers Market

For Deeper Insights, Find the Report in the Language that You want

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

[mitalipingale]

FutureWise Research published a report that analyzes Prognostic Biomarkers Market trends to predict the market's growth. The report begins with a description of the business environment and explains the commercial summary of the chain structure. Based on the market trends and driving factors presented in the report, clients will be able to plan the roadmap for their products and services taking into account various socio-economic factors.

[covid-safer-hotties]

Reference saved in our archive

An interesting potential diagnostic tool that deserves further study. Could be a clue to diagnosing or preventing long covid with some further understanding.

Abstract Objective As one of the remarkable host responses to SARS-CoV-2 infection, circulating microRNAs (miRNAs) represent important diagnostic and prognostic diseases biomarkers. The study is a step towards highlighting the role of miRNAs in COVID-19 pathogenesis and severity.

Methods In this case-control study, miRCURY LNA miRNA PCR plasma panel (168 miRNAs) was applied and the expression of the altered miRNAs was then analysed by quantitative real time PCR for 120 COVID-19 patients (30 mild, 30 moderate, 30 severe, and 30 critical) and 30 healthy subjects.

Results The initial screening showed that 30 miRNAs displayed altered expression, out of them, only eleven miRNAs (miR-885-5p, miR-141-3p, miR-21-5p, miR-127-3p, miR-99b-5p, let-7d-3p, miR-375, miR-1260a, miR-139-5p, miR-28-5p and miR-34a-5p) were dysregulated in the plasma of COVID-19 patients; all of them were significantly overexpressed. By applying ROC curve analysis, AUC for the eleven miRNAs were ranged from 0.65 to 0.83, and the AUC for the combined miRNAs was 0.93. Ten miRNAs (miR-141-3p, miR-181a-5p, miR-221-3p, miR-223-5p, miR99b-5p, Let-7d-3p, miR-375, miR-199a-5p, miR-139-5p and miR-28-5p) exhibited a significant change in their expression between different severity groups. Patients with positive outcome were found to have increased miR-375 and decreased miR-99b-5p expression levels. Bioinformatic prediction showed that, out of the eleven dysregulated miRNAs, five miRNAs (miR-139-5p, −34a-5p, −28-5p, −21-5p and −885-5p) have the ability to regulate at least two genes related to COVID-19 according to KEGG database.

Conclusion miRNAs are dysregulated in COVID-19 patients and associated with severity degree and patients’ outcome.

[many-to-mention10001]

What challenges are faced in biomarker analysis?

What challenges are faced in biomarker analysis? Issues include variability, limited sample sizes, and translating findings to clinical applications.

What regulatory guidelines govern biomarker studies? Standards are set by bodies like FDA, EMA, and ICH, emphasizing validation and reproducibility.

How are biomarkers classified? Into categories like diagnostic, prognostic, predictive, pharmacodynamic, and susceptibility biomarkers.

What is multiplex biomarker analysis? The simultaneous measurement of multiple biomarkers in a single sample.

How is the sample size determined for biomarker studies? Based on statistical power calculations and expected biomarker effect sizes.

[mordorintelligencemarketresearch]

The Biomarkers Industry: Transforming Healthcare with Precision Medicine

Biomarkers have emerged as a transformative force in the healthcare and biotechnology sectors, underpinning the shift toward precision medicine. These biological indicators, derived from measurable characteristics such as genes, proteins, or metabolites, provide critical insights into the health, disease progression, and therapeutic responses of individuals. The biomarkers industry is flourishing as advancements in medical science, diagnostics, and drug development continue to expand their utility across diverse clinical and research domains. 

The biomarkers market is projected to be valued at USD 56.72 billion in 2024 and is anticipated to grow to USD 87.64 billion by 2029, registering a compound annual growth rate (CAGR) of 9.09% during the forecast period from 2024 to 2029. 

Understanding Biomarkers and Their Importance 

Biomarkers, or biological markers, are measurable indicators of biological processes, pathogenic conditions, or pharmacologic responses to therapeutic interventions. They are categorized into three primary types: 

Diagnostic Biomarkers: Used to detect or confirm the presence of a disease or condition. 

Prognostic Biomarkers: Indicate the likely course or outcome of a disease. 

Predictive Biomarkers: Help forecast an individual's response to a specific treatment. 

These indicators play a critical role in early disease detection, personalized treatment planning, and monitoring therapeutic efficacy. The rising focus on precision medicine and targeted therapies has elevated the significance of biomarkers across healthcare disciplines. 

Key Drivers of Growth in the Biomarkers Industry 

1. Rising Prevalence of Chronic Diseases 

The global burden of chronic diseases, such as cancer, cardiovascular diseases, and diabetes, has driven the demand for effective diagnostic and therapeutic tools. Biomarkers enable early disease detection and personalized treatment approaches, addressing the growing need for efficient healthcare solutions. 

2. Advancements in Genomics and Proteomics 

The integration of genomics, proteomics, and metabolomics into healthcare has accelerated biomarker discovery and application. High-throughput technologies, such as next-generation sequencing (NGS) and mass spectrometry, have expanded the understanding of disease mechanisms, paving the way for novel biomarkers. 

3. Expansion of Precision Medicine 

Precision medicine aims to tailor medical treatments to individual characteristics, leveraging biomarkers to guide therapeutic decisions. This approach has gained traction across oncology, neurology, and infectious diseases, driving the adoption of biomarkers in clinical practice. 

4. Growth of Companion Diagnostics 

Companion diagnostics, which rely on biomarkers to identify patients likely to benefit from specific therapies, have become integral to drug development. Regulatory agencies encourage the co-development of biomarkers and therapies, further boosting the biomarker industry. 

5. Increasing Investments in Research and Development 

Pharmaceutical and biotechnology companies, along with academic institutions, are investing heavily in biomarker research to accelerate drug discovery, improve clinical trials, and develop innovative diagnostics. Government initiatives and private funding have also supported biomarker research, fostering industry growth. 

Applications of Biomarkers 

1. Drug Discovery and Development 

Biomarkers have revolutionized drug development by enabling targeted therapies, improving clinical trial design, and reducing attrition rates. They help identify patient populations likely to respond to treatment, facilitating efficient trials and accelerating regulatory approval. 

2. Disease Diagnosis and Monitoring 

In diagnostics, biomarkers improve accuracy and enable early detection of diseases. For instance, cancer biomarkers such as HER2 and PSA (prostate-specific antigen) are widely used for diagnosis and monitoring disease progression. 

3. Personalized Medicine 

By providing insights into an individual’s genetic makeup, biomarkers guide the selection of tailored therapies, enhancing treatment outcomes and minimizing adverse effects. In oncology, for example, biomarkers like EGFR and ALK help determine the suitability of targeted therapies. 

4. Predictive and Prognostic Tools 

Biomarkers predict disease risk or therapeutic outcomes, allowing for proactive interventions. Prognostic biomarkers, such as BRAF mutations in melanoma, provide valuable information about disease progression. 

5. Infectious Disease Management 

Biomarkers play a critical role in managing infectious diseases by identifying pathogen-specific markers and evaluating treatment efficacy. During the COVID-19 pandemic, biomarkers like D-dimer and CRP were used to assess disease severity and guide patient management. 

Challenges in the Biomarkers Industry 

1. Validation and Standardization 

Ensuring the accuracy, reproducibility, and clinical relevance of biomarkers remains a challenge. Rigorous validation processes and standardized protocols are essential for integrating biomarkers into clinical practice. 

2. High Development Costs 

The discovery and validation of biomarkers involve extensive research, advanced technologies, and regulatory compliance, making the process costly and time-consuming. 

3. Regulatory Hurdles 

Biomarkers must meet stringent regulatory requirements for clinical use, which can delay their approval and commercialization. Harmonizing global regulatory frameworks is critical to overcoming this challenge. 

4. Limited Accessibility in Emerging Markets 

Despite advancements, the adoption of biomarkers in emerging markets is limited due to inadequate healthcare infrastructure, lack of awareness, and high costs. Bridging this gap is vital to ensure equitable access to biomarker-based diagnostics and treatments. 

5. Ethical and Privacy Concerns 

The use of biomarkers in genomics and personalized medicine raises ethical and privacy concerns, particularly regarding data security and informed consent. Addressing these issues is crucial to building trust and ensuring responsible use. 

Emerging Trends in the Biomarkers Industry 

1. Integration of Artificial Intelligence and Machine Learning 

AI and machine learning are transforming biomarker discovery by analyzing vast datasets to identify novel biomarkers. These technologies enhance pattern recognition, accelerate research, and improve diagnostic accuracy. 

2. Liquid Biopsy Advancements 

Liquid biopsies, which detect biomarkers in blood or other bodily fluids, are gaining momentum as a non-invasive diagnostic tool. They offer real-time monitoring of disease progression and treatment response, particularly in oncology. 

3. Multi-Omics Approaches 

Combining genomics, proteomics, transcriptomics, and metabolomics provides a comprehensive understanding of disease biology, facilitating the discovery of robust biomarkers. 

4. Digital Biomarkers 

The rise of wearable devices and mobile health applications has introduced digital biomarkers, which collect real-time data on physiological and behavioral parameters, enhancing patient monitoring and disease management. 

5. Collaboration and Open Data Sharing 

Collaborative efforts between academia, industry, and regulatory bodies are fostering innovation in biomarker research. Open data-sharing initiatives are accelerating the discovery of biomarkers and promoting transparency. 

Conclusion 

The biomarkers industry is at the forefront of transforming healthcare, enabling early diagnosis, personalized treatment, and efficient drug development. As advancements in technology and research continue to expand the scope of biomarkers, their impact on improving patient outcomes and healthcare efficiency is undeniable. 

While challenges such as validation, costs, and regulatory complexities persist, emerging trends like AI integration, liquid biopsies, and multi-omics approaches offer promising solutions. The biomarkers industry will play a pivotal role in shaping the future of precision medicine, addressing unmet medical needs, and revolutionizing patient care on a global scale.    For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence: https://www.mordorintelligence.com/industry-reports/biomarkers-market 

[jcsmicasereports]

Comparison and significance of serum 7 cytokines in children with community-acquired common pneumonia and lobar pneumonia by Shi Changsong in Journal of Clinical Case Reports Medical Images and Health Sciences

Abstracts

Objective: To investigate the availability of seven serum cytokines, interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-17 (IL-17), interleukin-12-70 (IL-12P70), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) changes and significance in Common and lobular community acquired pneumonia (CAP). 

Methods: Fifty-three patients admitted to our hospital from April 2022 to July 2023 were selected as the observation group. According to the degree of pneumonia, they were divided into common pneumonia group (observation group 1), lobular pneumonia group (observation group 2), and children with fever (acute upper respiratory tract infection) during the same period were selected as the control group. The clinical data of the subjects in three groups (observation group 1, 2 and control group) were retrospectively analyzed. Temperature, length of stay, chest CT and other basic information were recorded. Fasting venous blood of three groups of children was collected and 7 cytokines levels were detected. The cytokine levels of the three groups were compared by one-way analysis of variance. 

Results: The hospital stay of lobar pneumonia group was significantly longer than that of common pneumonia group and fever group. There were no significant differences in IL-4, IL-6,IL-10, IL-17, IL-12P70, TNF-a and IFN-γ among lobular pneumonia group, common pneumonia group and fever group (P > 0.05). 

Conclusion: Lobar pneumonia prolongs the hospital stay of children. The cytokines IL-4,IL-6,IL-10,IFN-γ, IL-17,TNF-a and IL-12P70 showed no significant difference in lobular pneumonia group, common pneumonia group and fever group. According to the World Health Organization, pneumonia killed 920,000 children under the age of five in 2016, 98% of whom were in developing countries. Pneumonia is also one of the main causes of death among children < 5 years old in China, and most of them are lobular community acquired pneumonia (CAP)[1]. At present, there are few studies on biomarkers used to assess disease severity and prognosis [2]. Cytokines are major regulatory factors of inflammatory response, which play a role in amplifying, transducing and coordinating pro-inflammatory signals, leading to synchronous expression of molecular effectors and regulating autoimmune responses [3]. Previous studies have shown that the prognostic value of changes in cytokine levels is correlated with the severity of pneumonia [4]. The objective of this study was to retrospectively analyze and compare cytokine levels in children with common pneumonia and lobar pneumonia.

Data and methods

General Information:The medical records of 53 children with CAP who were hospitalized in the pediatric respiratory department of our hospital from April 2022 to July 2023 were collected. According to the degree of pneumonia, they were divided into common pneumonia group and lobar pneumonia group. Children with fever during the same period were selected as the control group, and basic information such as temperature at admission, length of stay, duration of medical history and chest CT were recorded. Cytokine levels were determined by the key Laboratory of hematological Pathology of our hospital. This study was approved by the Ethics Committee of Henan Provincial People's Hospital (2023) No. 65.

Inclusion and exclusion criteria for children with pneumonia:

Inclusion criteria: 1) The diagnostic criteria of community-acquired pneumonia and lobar pneumonia in children in the 8th edition of Zhufutang Practical Pediatrics were met; 2) Complete clinical data; Exclusion criteria: 1) combined with other lung diseases, such as asthma and tuberculosis; 2) Previous immune disease, unexplained long-term fever, joint swelling and pain; 3) A recent or longterm history of glucocorticoid use; 4) Immunomodulators and immunosuppressants such as immunoglobulin and interferon have been applied in the past 2 months.

Statistical Processing:

All the data of the patients were recorded, and the differences of each index between the two groups were analyzed using Graphpad Prism 8. Counting data is expressed as example (%); The measurement data were expressed as mean ± standard deviation (x±s), and the cytokine levels of the three groups were examined by one-way ANOVA for inter-group comparison. P < 0.05 was statistically significant. 

Results: Compared with the other 2 groups, the length of hospital stay in the lobar pneumonia group was significantly increased, with statistical significance (P < 0.05), while there was no statistical significance in other general data (P > 0.05). Compared with lobular pneumonia group, common pneumonia group and fever group, there were no significant differences in serum cytokines in IL-4,IL-6,IL-10, IL-17, IL12P70, TNF-a and IFN-γ (P > 0.05).

Discussion: CAP is a common infectious disease in childhood, especially in infants and young children. It is the most common cause of hospitalization in children and the first cause of death in children under 5 years old. For hospitalized children or areas with good conditions, the evaluation of CAP severity should also be based on the scope of lung lesions, the presence of hypoxemia, and the presence of internal and external pulmonary complications[5]. This study was mainly based on the clinical symptoms of pneumonia and the range of chest imaging lesions as a grouping basis to determine the severity of pneumonia. The results of this study found that the length of hospital stay in the fever group, the common pneumonia group and the lobular pneumonia group was different in pairwise comparison, and the length of hospital stay in the lobular pneumonia group was significantly longer than that in the other two groups, indicating that the scope of chest imaging lesions may affect the length of hospital stay and treatment time, which has guiding significance for our clinical evaluation of the length of hospital stay for pneumonia.

Cytokines, including types Th1 (IL-2, IFN-γ, TNF-α, and IL-18) and Th2 (IL-4, IL-5, IL-6, IL-10, and IL-13), can recruit or activate B, T, and NK cells to initiate and amplify inflammatory/immune responses. Thus providing an important function in host defense against bacterial or viral infections [6]. Cytokines participate in the pathogenesis of pneumonia by interacting with organ receptors [7], leading to a decline in respiratory system related functions. Studies have found that TNF-α, IFN-γ, IL-6, IL-8, IL-10, IL-1β and other cytokines have been proven to be correlated with adult CAP severity [8]. However, Luo Zhengxiu et al. retrospectively analyzed and compared the serum cytokine levels between the severe children group and the non-severe CAP group and found no statistically significant differences in the levels of IL-6, IL-2, IL-4, IL-10, TNF-α, IFN-γ and IL-17A between the two groups [9]. Therefore, there is no consensus on the effect of cytokines on the prognosis of childhood pneumonia. This study found no correlation between IL-4, IL-6, IL-10, IFN-γ, IL-17, TNF-α, and IL-12P70 and the severity of pneumonia. Due to the single-center and small sample data in this study, the correlation between these cytokines and the severity of pneumonia needs further study.

[doctorsudiptymohanty]

Genomic Contextualization: Personalized Treatment Protocols in Modern Internal Medicine

 Introduction

Genomic contextualization is a cornerstone of modern internal medicine, enabling the development of personalized treatment protocols that are tailored to an individual's unique genetic profile. This approach leverages advances in genomic technologies, bioinformatics, and data analytics to provide precise and effective healthcare. Here, we delve into the concept of genomic contextualization and its implications for personalized treatment protocols in internal medicine.

 The Role of Genomics in Personalized Medicine

Genomics plays a pivotal role in personalized medicine by providing a detailed understanding of an individual's genetic makeup. This information can be used to predict disease susceptibility, diagnose conditions accurately, and select the most effective treatments. The Human Genome Project and subsequent genomic initiatives have laid the foundation for this approach, enabling the identification of genetic variants associated with various diseases.

Whole exome sequencing (WES) and targeted sequencing are particularly useful in clinical practice, as they balance cost and benefit by focusing on protein-coding regions of the genome. These techniques have been integrated into clinical genetics laboratories and large-scale projects such as the 1000 Genome Project and the Exome Aggregation Consortium (ExAC) to catalog population variants and identify diseases associated with rare genetic variants.

 Genomic Contextualization and Disease Management

Genomic contextualization involves correlating an individual's genetic profile with clinical-pathological indexes to devise personalized diagnostic, prognostic, and therapeutic strategies. This approach is particularly beneficial in managing complex diseases such as cancer, diabetes, and endocrine disorders.

In oncology, for example, precision medicine involves identifying oncogenes and tumor suppressor genes to design targeted therapies. Multi-regional sequencing of tumors reveals genetic heterogeneity, allowing for the selection of patients who may benefit from biomarker-driven therapies. Studies like the NCI MATCH trial and the TAPUR study demonstrate the potential of this approach in improving patient outcomes by matching genetic aberrations with targeted therapies.

 Pharmacogenomics and Personalized Treatment

Pharmacogenomics, a subfield of precision medicine, studies how genetic variations affect an individual's response to medications. This knowledge enables healthcare providers to select medications and adjust dosages based on a patient's genetic makeup, maximizing therapeutic benefits while minimizing adverse reactions. For instance, in diabetes management, pharmacogenomics can guide the use of metformin and other antidiabetic drugs, ensuring optimal efficacy and safety.

 Integration of Advanced Technologies and Data Analytics

The integration of advanced technologies such as next-generation sequencing (NGS), machine learning, and artificial intelligence (AI) is crucial for genomic contextualization. These tools facilitate large-scale genomic sequencing, predictive modeling, and the analysis of vast datasets to identify disease patterns and predict treatment responses.

Machine learning algorithms can analyze genomic data in conjunction with clinical and environmental factors to develop personalized treatment algorithms. Telehealth platforms and digital health applications enable real-time monitoring of patient health metrics, medication adherence, and lifestyle modifications, further enhancing patient-centered care.

 Ethical and Regulatory Considerations

While genomic contextualization offers significant benefits, it also raises ethical and regulatory concerns. Ensuring patient data privacy and security is paramount, given the sensitive nature of genetic information. Regulatory frameworks must be established to govern the use of genomic data in healthcare, ensuring compliance with laws such as HIPAA and preventing the misuse of genetic information.

 Future Directions and Challenges

The future of genomic contextualization in internal medicine is promising but also presents several challenges. There is a need for continued research to refine these approaches and address issues such as data quality, class imbalance, and the integration of diverse data sources.

Expanding genomic research, biomarker discovery, and therapeutic innovations will be essential for enhancing treatment efficacy and disease prevention. Additionally, educating healthcare professionals in genomics and precision medicine will be critical for the widespread adoption and effective implementation of these personalized treatment protocols.

 Conclusion

Genomic contextualization is revolutionizing internal medicine by enabling the development of personalized treatment protocols that are tailored to an individual's unique genetic profile. By integrating genomic information with advanced technologies and data analytics, healthcare providers can offer precise and effective care, improving patient outcomes and enhancing the quality of life for individuals with complex medical conditions. As this field continues to evolve, addressing ethical and regulatory concerns while ensuring the accuracy and reliability of genomic data will be essential for maximizing the benefits of personalized medicine.

[biomedres]

Is Pentraxin 3 A Marker in Pathogenesis of Metabolic Syndrome?

Is Pentraxin 3 A Marker in Pathogenesis of Metabolic Syndrome? in Biomedical Journal of Scientific & Technical Research

Pentraxin 3 (PTX3) is an acute-phase protein that is structurally similar to C-reactive protein (CRP). Macrophages, endothelial cells, and adipocytes all produce PTX3 in response to inflammatory stimuli, but hepatocytes are the main source of CRP. PTX3 could play a role in the genesis of obesity, metabolic syndrome (MetS), and CRP because obesity and MetS are chronic inflammatory diseases [1]. MetS is a group of risk factors that includes glucose intolerance, abnormal lipid profiles, hypertension, and abdominal obesity [2- 6]. Each of these factors has been linked to atherosclerosis and cardiovascular disease. The majority of current research has found a link between MetS components and inflammatory mediators such as interleukin-6, tumor necrosis factor-α, and CRP [7]. Furthermore, serum CRP levels were shown to be greater in individuals with more risk factors for MetS, and higher serum CRP levels were related to higher occurrence of cardiovascular events, reflecting the prognostic relevance of MetS severity [8]. In particular, many types of cells, including macrophages, dendritic cells, neutrophils, adipose cells, fibroblasts, and vascular endothelial cells, have been reported to produce PTX-3, a newly recognized acute-phase reactant that is structurally and functionally similar to CRP [9]. The link between MetS and PTX-3 hasn’t been well investigated, and the available evidence appears to be discordant. Several investigations have found a link between MetS components and inflammatory mediators such as interleukin-6, tumor necrosis factor-α, and CRP [7]. The hs-CRP is the most well-known and validated of these inflammatory biomarkers. Insulin resistance, endothelial dysfunction, and unfavorable cardiovascular events have all been linked to high levels of hs-CRP [10,11].

For more articles in Journals on Biomedical Sciences click here bjstr

Follow on Twitter : https://twitter.com/Biomedres01 Follow on Blogger : https://biomedres01.blogspot.com/ Like Our Pins On : https://www.pinterest.com/biomedres/

[mitalipingale]

FutureWise Research published a report that analyzes Prognostic Biomarkers Market trends to predict the market's growth. The report begins with a description of the business environment and explains the commercial summary of the chain structure. Based on the market trends and driving factors presented in the report, clients will be able to plan the roadmap for their products and services taking into account various socio-economic factors.

[harshnews]

Neurological Biomarkers Market Size, Share, Trends, Growth and Competitive Analysis

"Neurological Biomarkers Market – Industry Trends and Forecast to 2030

Global Neurological Biomarkers Market, By Product Type (Genomics Biomarker, Proteomics Biomarker, Imaging Biomarker, Metabolomics Biomarker, Others), Indication (Spinal Muscular Atrophy, Parkinson's Disease, Schizophrenia, Huntington's Disease, Alzheimer's Disease, Depression, Multiple Sclerosis), Imaging Techniques (Transcranial Magnetic Stimulation, Diffusion Tensor Imaging, Conventional Structural MRI, Functional Magnetic Resonance Imaging, Positron Emission Tomography), Services (Sample Preparation, Assay Development, Biomarker Validation and Testing), End- User (Clinical Diagnostics, Pharmaceutical and Biotechnology Companies, Research Organizations) – Industry Trends and Forecast to 2030.

Access Full 350 Pages PDF Report @

**Segments**

- **Product Type**: The market can be segmented based on the product type into neurogenomics, proteomics, metabolomics, and genomics. - **Application**: Segmentation by application includes diagnostics, personalized medicine, drug discovery, prognostics, and others. - **End-User**: The market can be categorized by end-users such as hospitals, research institutes, diagnostic laboratories, and others.

Neurological biomarkers play a crucial role in the early and accurate diagnosis of various neurological disorders. The market is segmented based on several key factors that impact the demand and growth of neurological biomarkers. Product type segmentation includes neurogenomics, proteomics, metabolomics, and genomics, each playing a unique role in identifying biomarkers associated with neurological conditions. Application-based segmentation covers diagnostics, personalized medicine, drug discovery, and prognostics, highlighting the diverse utility of neurological biomarkers across different medical settings. End-user segmentation includes hospitals, research institutes, diagnostic laboratories, and other healthcare facilities that utilize neurological biomarkers for improved patient care and disease management.

**Market Players**

- **Thermo Fisher Scientific Inc.**: Thermo Fisher Scientific Inc. is a prominent player offering a wide range of neurological biomarker solutions for research and clinical applications. - **Merck KGaA**: Merck KGaA is a key market player known for its innovative neurological biomarker products and services aimed at advancing neurology research. - **Abbott Laboratories**: Abbott Laboratories is recognized for its contributions to the neurological biomarkers market through the development of cutting-edge diagnostic tools. - **F. Hoffmann-La Roche Ltd**: F. Hoffmann-La Roche Ltd is a leading player offering comprehensive neurological biomarker solutions for precision medicine and drug development. - **QIAGEN**: QIAGEN is a significant player providing high-quality biomarker technologies and assays for neurological research and diagnostics.

These market players are at the forefront of driving innovation and advancements in the field of neurological biomarkersThermo Fisher Scientific Inc. holds a prominent position in the neurological biomarkers market, offering a diverse range of solutions tailored for both research and clinical applications. The company's extensive portfolio encompasses neurogenomics, proteomics, metabolomics, and genomics products that cater to the specific needs of studying neurological disorders. Thermo Fisher Scientific's commitment to innovation and quality has solidified its reputation as a trusted provider of neurological biomarker solutions. By staying at the forefront of technological advancements and scientific research, the company continues to drive progress in the field of neurology.

Merck KGaA is another key player that stands out in the neurological biomarkers market due to its focus on delivering innovative products and services designed to advance neurology research. The company's dedication to developing cutting-edge neurological biomarker solutions has positioned it as a significant contributor to the market's growth and development. Merck KGaA's strategic collaborations and investment in research and development have enabled it to introduce novel approaches and technologies that have the potential to revolutionize the way neurological disorders are diagnosed and treated.

Abbott Laboratories has made substantial contributions to the neurological biomarkers market by pioneering the development of state-of-the-art diagnostic tools that aid in the early detection and management of neurological conditions. The company's unwavering commitment to improving patient outcomes through the provision of reliable and accurate neurological biomarker solutions has earned it a strong reputation in the industry. Abbott Laboratories' focus on leveraging scientific expertise and technological innovation underscores its dedication to addressing unmet medical needs in the neurology space.

F. Hoffmann-La Roche Ltd has established itself as a leading player in the neurological biomarkers market by offering comprehensive solutions that support precision medicine and drug development in neurology. The company's commitment to advancing neurology through the development of innovative biomarker technologies underscores its dedication to addressing the evolving needs of healthcare providers and patients alike. F. Hoffmann-La Roche Ltd's holistic approach to neurological biomarkers encompasses a wide range of applications, from diagnostics to ther**Global Neurological Biomarkers Market Analysis**

- The global neurological biomarkers market is witnessing significant growth attributed to rising prevalence of neurological disorders and increased investment in neuroscience research. - Genomics biomarkers segment is expected to dominate the market, driven by advancements in genomics technology and the ability to identify genetic markers associated with neurological conditions. - Alzheimer's Disease indication holds a substantial share due to the high prevalence of the disease globally and the urgent need for effective diagnostic and treatment solutions. - Imaging techniques such as functional magnetic resonance imaging and positron emission tomography are gaining traction for their ability to provide detailed insights into neurological conditions and facilitate personalized treatment approaches. - Pharmaceutical and biotechnology companies are the key end-users of neurological biomarkers, leveraging these tools for drug discovery, clinical trials, and precision medicine initiatives.

The global neurological biomarkers market is poised for substantial growth in the coming years, fueled by technological advancements, increasing disease burden, and growing focus on personalized medicine in neurology. Genomics biomarkers are anticipated to lead the market, supported by their ability to provide valuable genetic insights into neurological disorders and aid in the development of targeted therapies. The emergence of advanced imaging techniques like functional MRI and PET imaging is revolutionizing neurology by enabling precise diagnosis and monitoring of neurological conditions.

Alzheimer's Disease, a prevalent neurological disorder, is expected to drive significant demand for biomarkers, given the urgent need for early detection and disease management strategies. Pharmaceutical and biotechnology companies are investing heavily in neurological biomarkers for drug

Table of Content:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Global Neurological Biomarkers Market Landscape

Part 04: Global Neurological Biomarkers Market Sizing

Part 05: Global Neurological Biomarkers Market Segmentation by Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Neurological Biomarkers Key Benefits over Global Competitors:

The report provides a qualitative and quantitative analysis of the Neurological Biomarkers Market trends, forecasts, and market size to determine new opportunities.

Porter’s Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.

Top impacting factors & major investment pockets are highlighted in the research.

The major countries in each region are analyzed and their revenue contribution is mentioned.

The market player positioning segment provides an understanding of the current position of the market players active in the Personal Care Ingredients

Browse Trending Reports:

Mhealth Solutions Market Telecom Cloud Billing Market Industrial Cooking Fire Protection Systems Market Food Manufacturing Market Natural Surfactant Market Industrial Networking Solutions Market Facility Management Market Cathode Materials Market High Purity Gases Market Cassava Starch Market Embedded Connectivity Solutions Market Central Fill Pharmacy Automation Market Rfid In Healthcare Market Virtual Pipeline Systems Market Fiberoptic Phototherapy Equipment Market Suture Passer Market Baby Apparel Market Peanut Allergy Treatment Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[biotech-news-feed]

New biomarker test aims to improve early-stage melanoma treatment #BioTech #science